This Massachusetts-based biopharmaceutical company announced hundreds of layoffs last week. Here's what the CEO said about it ...

Companies sometimes miss the mark when it comes to telling employees they’re out of a job. From accidental goodbyes to ...

A spokesperson for the Department of Health and Human Services confirmed that Dr. Vinay Prasad, who led the FDA’s Center for ...

Since Dr. Vinay Prasad’s appointment as a key political voice within FDA, the tone of U.S. biotech policy has shifted from ...

F.D.A. resignation: The Food and Drug Administration’s top vaccine and gene therapy official resigned on Tuesday after a ...

Desai believes it's a "good time for fixed income," but wants to see more realistic investor expectations. Generations out there in the past got accustomed to getting just 1% -2.5% for investing in 10 ...

The abrupt exit of the former CBER director, who quickly made his mark at the agency with several high-profile and ...

The Food and Drug Administration’s polarizing vaccine chief is leaving the agency after a brief tenure that drew the ire of ...

The FDA has missed the date for Coya Therapeutics’ investigational new drug (IND) application, citing a lack of resources and ...

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

Review the current Sarepta Therapeutics Inc (1SRPT:XMIL) dividend yield and history to decide if 1SRPT is the best investment for you.